Friday, April 01, 2011

Honey a Low Cost Treatment for HIV Patients with Venous Ulcers

Derma Sciences Advanced Wound Care Products Featured in Five Poster Presentations at the Diabetic Foot Global Conference 2011

PRINCETON, N.J.--(EON: Enhanced Online News)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that five scientific abstracts based on commercial and development-stage products in the Company’s line of wound dressings were presented at the annual Diabetic Foot Global Conference (DFCON), held in Los Angeles March 24-26…

About the MEDIHONEY® Poster Presentations

MEDIHONEY®, the leading global brand of honey-based wound care, is a line of wound and burn dressings containing active Manuka (Leptospermum) honey from New Zealand. This unique species of medical-grade honey has been shown in several large-scale, randomized controlled clinical studies to possess unique qualities that help to initiate healing in stalled wounds, and assist with fast debridement of non-viable tissue.

The Clinical Use of Leptospermum Honey on Neuropathic Forefoot Ulcerations in Patients with Diabetes Mellitus; by Steven Kavros, DPM, Mayo Clinic, Rochester, MN

The purpose of this study was to evaluate the healing of forefoot ulcerations with the use of MEDIHONEY® in the setting of diabetic neuropathy. The study found that the MEDIHONEY® group healed at a significantly faster rate than the control group; the mean healing time was 77 days (95% CI, 73.1 – 80.89 days) versus 96 days (95% CI, 91.3 – 100.89 days) for the control group. There was a significant healing rate with the use of MEDIHONEY® versus control (p< 0.0001).

The Use of Active Leptospermum Honey Dressings on Challenging Patients in an Indigent Wound Clinic; by LaVerne Graves, RN, BSW, CWS; Diane Maggio, RN, BSN, CRRN, CWON, Atlanticare Regional Medical Center; Princeton, NJ

Also presented was data collected from case reports chronicling MEDIHONEY® dressing usage in an indigent clinic on patients with the co-morbidities of HIV and highly exudating venous ulcers. The study concluded that the outcomes of MEDIHONEY® usage in these cases were successful closure of wounds that restored quality of life to patients and cost savings with decreased healing times...

No comments: